Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5515584 | 1.00 | POLB (0.49) | POLBMEN1KMT2ACNR2NR1H4 | |
| SCHEMBL5515591 | 1.00 | POLB (0.49) | POLBMEN1KMT2ACNR2NR1H4 | |
| SCHEMBL5527593 | 0.90 | LMNA (0.48) | POLBKMT2ACNR2LMNA | |
| SCHEMBL5527590 | 0.90 | LMNA (0.48) | POLBKMT2ACNR2LMNA | |
| SCHEMBL5527587 | 0.90 | LMNA (0.48) | POLBKMT2ACNR2LMNA | |
| SCHEMBL5526205 | 0.88 | SLC6A3 (0.45) | CNR2NR1H4 | |
| SCHEMBL5520705 | 0.88 | CNR2 (0.44) | CNR2NR1H4KDM1ATP53 | |
| SCHEMBL5520711 | 0.88 | CNR2 (0.44) | CNR2NR1H4KDM1ATP53 | |
| SCHEMBL5526202 | 0.88 | SLC6A3 (0.45) | CNR2NR1H4 | |
| SCHEMBL5520702 | 0.88 | CNR2 (0.44) | CNR2NR1H4KDM1ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | claimed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | POLB 2911/4885MEN1 3887/4885KMT2A 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.